Corpus overview


Overview

MeSH Disease

Hypertension (58)

Pneumonia (52)

Disease (37)

Death (26)

Infections (25)


Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 59
    records per page




    Aneurysmal Subarachnoid Haemorrhage After COVID-19 Infection MESHD

    Authors: Sajjad Muhammad; Soheil Naderi; Mostafa Ahmadi; Askar Ghorbani; Daniel Hänggi

    doi:10.21203/rs.3.rs-48374/v1 Date: 2020-07-24 Source: ResearchSquare

    BackgroundSARS-CoV-2 virus infection MESHD leads to a severe and dysbalanced inflammatory response with hypercytokinemia and immunodepression. Systemic inflammation MESHD due to viral infections MESHD can potentially cause vascular damage including disruption of blood SERO-brain barrier (BBB) and alterations in coagulation system that may also lead to cardiovascular and neurovascular events. Here, we report the first case of COVID-19 infection MESHD leading to aneurysmal subarachnoid haemorrhage (aSAH). Case DescriptionA 61-year-old woman presented with dyspnea MESHD dyspnea HP, cough MESHD cough HP and fever MESHD fever HP. She was over weight with Body MESHD mass-index of 34 and history of hypertension MESHD hypertension HP. No history of subarachnoid hemorrhage MESHD subarachnoid hemorrhage HP in the family. She was admitted in ICU due to low oxygen saturation (89%). A chest CT showed typical picture of COVID-19 pneumonia MESHD pneumonia HP. Oropharyngeal swab with a PCR-based testing was COVID-19 positive. She was prescribed with favipiravir and hydroxychloroquine in Addition to oxygen support. On second day she experienced sudden headache MESHD headache HP and losst conciousness. A computer tomography (CT) with CT-angiography revealed subarachnoid haemorrhage in basal cisterns from a ruptured MESHD anterior communicating artery aneurysm MESHD. The aneurysm MESHD was clipped microsurgically through a standard pterional approach and the patient was admitted again to intensive care unit for further intensive medical treatment. Post-operative the patient showed slight motor dysphasia HP. No other neurological deficits.ConclusionAneurysmal subarachnoid haemorrhage secondary to COVID-19 infection MESHD might be triggered by systemic inflammation MESHD. COVID-19 infection MESHD could be one of the risk factors leading to instability and rupture MESHD of intracranial aneurysm MESHD.

    SECOND WEEK METHYL-PREDNISOLONE PULSES IMPROVE PROGNOSIS IN PATIENTS WITH SEVERE CORONAVIRUS DISEASE MESHD 2019 PNEUMONIA MESHD PNEUMONIA HP: AN OBSERVATIONAL COMPARATIVE STUDY USING ROUTINE CARE DATA.

    Authors: Guillermo Ruiz-Irastorza; Jose-Ignacio Pijoan; Elena Bereciartua; Susanna Dunder; Jokin Dominguez; Paula Garcia-Escudero; Alejandro Rodrigo; Carlota Gomez-Carballo; Jimena Varona; Laura Guio; Marta Ibarrola; Amaia Ugarte; Agustin Martinez-Berriotxoa

    doi:10.1101/2020.07.16.20152868 Date: 2020-07-23 Source: medRxiv

    OBJECTIVE: To analyze the effects of a short course of methyl-prednisolone pulses (MP) during the second week of disease MESHD (week-2) on the clinical course of patients with severe coronavirus disease MESHD 2019 (COVID-19) pneumonia MESHD pneumonia HP. DESIGN: Comparative observational study using data collected from routine care. SETTING: Hospital Universitario Cruces, a tertiary level University hospital at Barakaldo, Bizkaia, Spain. PARTICIPANTS: All patients with COVID-19 pneumonia MESHD pneumonia HP admitted between 1st March and 30th April 2020 to the services of Infectious Diseases MESHD and Internal Medicine. INTERVENTIONS: Treatment with week-2-MP (125-250 mg/d for 3 consecutive days with no subsequent tapering) vs. standard of care. MAIN OUTCOMES MEASURES: Time to death MESHD and time to death MESHD or endotracheal intubation. RESULTS: Two hundred and forty-two patients with confirmed COVID-19 pneumonia MESHD pneumonia HP and elevated inflammatory markers at admission were included in the study. Sixty-one patients (25%) received week-2-MP. Twenty-two patients (9%) died during the study period. Thirty-one patients (12.8%) suffered death MESHD or intubation. The adjusted HR for death MESHD was 0.35 (95%CI 0.11 to 1.06, p= 0.064) for patients in the week-2-MP group. The adjusted HR for death MESHD or intubation week-2-MP was 0.33 (95%CI 0.13 to 0.84, p=0.020) for patients in the week-2-MP group. These differences were seen in the subcohort of patients with a SaO2/FiO2 at day 7 lower than the median of the whole population: HR 0.31, 95% CI 0.08 to 1.12, p=0.073 and HR 0.34, 95%CI 0.12 to 0.94, p=0.038, respectively, but not in patients with higher SaO2/FiO2. Other predictors of the final outcomes were arterial hypertension MESHD hypertension HP, SaO2/FiO2, high-risk CURB65 scores and the use of non-pulse glucocorticoids. Non-pulse glucocorticoids were a predictor of infections MESHD (OR 4.72, 95%CI 1.90 to 11.80, p<0.001), while week-2-MP were not (OR 1.04, 95%CI 0.40 to 2.70, p=0.938). CONCLUSIONS: Week-2-MP are effective in improving the prognosis of patients with COVID-19 pneumonia MESHD pneumonia HP with features of inflammatory activity and respiratory deterioration entering the second week of disease MESHD. The recognition of this high-risk population should prompt early use of MP at this point. REGISTRATION: This study has been registered in the EU PAS Register with the number EUPAS36287.

    Identification of Risk Factors for in-hospital Death MESHD of COVID - 19 Pneumonia MESHD Pneumonia HP

    Authors: Zhigang Wang; Zhiqiang Wang

    doi:10.21203/rs.3.rs-42478/v1 Date: 2020-07-13 Source: ResearchSquare

    Objective: To examine the clinical characteristics and identify independent risk factors for in-hospital mortality of 2019 novel coronavirus (COVID-19) pneumonia MESHD pneumonia HP.Methods: A total of 156 patients diagnosed with COVID-19 pneumonia MESHD pneumonia HP at the central Hospital of Wuhan from January 29, 2020, to March 20, 2020 were enrolled in this single-centered retrospective study. Their epidemiological parameters, clinical presentations, underlying diseases MESHD, laboratory test results and disease MESHD outcomes were collected and analyzed. Results: The median age TRANS of enrolled patients was 66. Underlying diseases MESHD were identified in 101 patients, with hypertension MESHD hypertension HP being the most common one, followed by cardiovascular disease MESHD and diabetes. The most common symptoms identified upon admission were fever MESHD fever HP, cough MESHD cough HP, dyspnea MESHD dyspnea HP and fatigue MESHD fatigue HP. Compared to survival cases, patients who dead during hospitalization had higher plasma SERO levels of D-dimer, creatinine, creatine kinase, lactate dehydrogenase, lactate and lower percentage of lymphocytes (LYM [%]), platelet count and albumin levels. Most enrolled patients received anti-biotics and anti-viral treatment. In addition, 60 patients received corticosteroid and 51 received intravenous immunoglobulin infusion. 44 patients received noninvasive ventilation, 19 received invasive ventilation. Respiratory failure HP was the most frequently observed complication (106 [67.9%]), followed by sepsis MESHD sepsis HP (103 [66.0%]), acute respiratory distress HP syndrome MESHD (ARDS) (67 [42.9%]) and septic shock MESHD shock HP (50 [32.1%]). Multivariable regression suggested that advanced age TRANS (OR [odds ratio]= 1.059, 95% CI [confidence interval]: 1.011-1.110, P= 0.016) and elevated lactate level upon admission (OR= 2.411, 95% CI: 1.177-4.941, P= 0.016) were independent risk factors for in-hospital mortality for COVID-19 infection MESHD. Meanwhile, increased LYM (%) at admission (OR= 0.798, 95% CI: 0.728-0.876, P< 0.001) indicated a better prognosis. Conclusions: In this study, we discovered that age TRANS, LYM (%) and lactate level upon admission were independent factors that could influence in-hospital mortality rate.

    Early Diagnosis and Clinical Significance of Acute Cardiac Injury - Under the Iceberg: A Retrospective Cohort Study of 619 Non-critically Ill Hospitalized COVID-19 Pneumonia MESHD Pneumonia HP Patients

    Authors: Yang Xie; Sichun Chen; Xueli Wang; Baige Li; Tianlu Zhang; Xingwei He; NingLing Sun; Luyan Wang; Hesong Zeng; Yin Shen

    doi:10.1101/2020.07.06.20147256 Date: 2020-07-07 Source: medRxiv

    Rationale: Coronavirus disease MESHD 2019 (COVID-19) can cause a viral pneumonia MESHD pneumonia HP together with other extrapulmonary complications. Acute cardiac related injury MESHD (ACRI) is common in hospitalized COVID-19 patients. Objective: To explain the pathological mechanism of ACRI and improve the treatment strategy by retrospectively observing the factors associated with ACRI and factors affecting the prognosis of ACRI with COVID-19 at an early stage. Methods: 619 COVID-19 patients were from Tongji Hospital, Wuhan. T test was used for continuous variables while Chi-square test for categorical factors. Univariable and multivariable logistic regression models were applied to estimate odds ratio (OR) with 95% confidence interval (CI). Results: Among the 619 OOS Level-I hospitalized COVID-19 patients, 102 (16.5%) were defined as ACRI (stage-1: 59 cases, stage-2: 43 cases). 50% of ACRI patients developed into severe cases and 25 patients died (CFR=24.5%), 42 times that of non-ACRI patients. Elderly TRANS (OR=2.83, P<0.001) , HTN (OR=2.09, P=0.005), {gamma}-globulin (OR=2.08, P=0.004), TCM (OR=0.55, P=0.017), PLT (OR=2.94, P<0.001) and NLR (OR=2.20, P=0.004) were independently correlated with ACRI. SBP[≥]140, dyspnea MESHD dyspnea HP, DM, smoking history were correlated with ACRI-stage2 only. In the prognostic subgroup analysis of ACRI patients,{gamma}-globulin treatment could prolong LOS. TCM (OR=0.26, P=0.006), SBP[≥]160 (OR= 22.70, P=0.005), male TRANS (OR=2.66, P=0.044) were associated with severe illness while corticosteroids treatment (OR=3.34, P=0.033) and male TRANS (OR=4.303, P=0.008) with death MESHD. Surprisingly, we found the mortality of non- elderly TRANS patients is higher than elderly TRANS (32.4% VS 20.0%, P=0.164), and both IKF and RASI treatment were not correlated with any prognostic indicators including severe, death MESHD and LOS. Conclusion: This study observed that several non-traditional issues were associated with early cardiac injury in COVID-19 while many traditional cardiovascular risk factors were not. Besides elderly TRANS and male TRANS, hypertension MESHD hypertension HP was confirmed to be the most important risk factor.

    Successful treatment of a critically ill patient with COVID-19 using tocilizumab and human umbilical cord mesenchymal stem cells: a case report

    Authors: Lei Ye; Ji-Qiu Wen; Song-Qing He; Yong-Chun Xu; Yuan-Cheng Hong; Fang-Yu Wang; Jiong Liu

    doi:10.21203/rs.3.rs-39985/v1 Date: 2020-07-02 Source: ResearchSquare

    Background A worldwide outbreak of coronavirus disease MESHD 2019 (COVID-19) has drawn global attention. However, up to now, no standard and effective therapy are available. Case presentation A 62-year-old man with a history of hypertension MESHD hypertension HP and diabetes was diagnosed with COVID-19 pneumonia MESHD pneumonia HP. He suffered from obvious shortness of breath and severe hyoxemia. Normal treatments like supportive therapy and antiviral drugs didn’t seem to improve his conditions. Then, he was given tocilizumab and human umbilical cord mesenchymal stem cells. After that, his respiratory symptoms and lung infectious lesions gradually subsided, and he was successfully discharged eventually. Conclusions For critically ill COVID-19 patients, immunological treatment like tocilizumab human umbilical cord mesenchymal stem cells should be considered.

    On two cases of atypical respiratory distress HP in eastern Democratic Republic of the Congo months before the COVID-19 pandemic was declared: Could SARS-Cov-2 have been already spreading? Case report

    Authors: Guy-Quesney MATESO; Marius BAGUMA; Pacifique MWENE-BATU; Ghislain MAHESHE BALEMBA; Fabrice NZABARA; Samuel MAKALI; Aline BEDHA; Bonheur FURAHA; Jimmy MINANI; Christian TSHONGO MUHINDO; Espoir BWENGE MALEMBAKA; Mannix Imani MASIMANGO; Tony Akilimali SHINDANO; Justin Cirhuza CIKOMOLA; Kanigula MUBAGWA

    doi:10.21203/rs.3.rs-39772/v1 Date: 2020-07-01 Source: ResearchSquare

    BackgroundPredictions have been made that Africa would be the most vulnerable continent to the novel coronavirus disease MESHD 2019 (COVID-19). Interestingly, the spread of the disease TRANS disease MESHD in Africa seems to have been delayed and initially slower than in many parts of the World. Here we report on two cases which make us suspect that COVID-19 might have been present in our region before the official declaration of the disease MESHD in December 2019.Case presentationThese two cases (one 55-year-old man and one 25-year-old woman) of acute respiratory distress HP secondary to atypical pneumonia MESHD pneumonia HP were seen in Bukavu, in eastern Democratic Republic of the Congo (DRC), between September and December 2019. One patient had returned from China and the other had close contacts TRANS with travellers from China in the 2 weeks prior to the onset of symptoms TRANS. In either case, the aetiology could not be accurately determined. However, the two cases presented a clinical picture (progressive dyspnoea, preceded by dry cough MESHD cough HP and fever MESHD fever HP) and laboratory changes (procalcitonin within the normal range, slight inflammation MESHD, and lymphopenia MESHD lymphopenia HP) compatible with a viral infection MESHD. The chest X-Rays series of the first patient showed lesions (reticulations, ground glass, and nodules ≤ 6 mm) similar to those found in COVID-19. In addition, unlike the 25-year-old female TRANS patient who had no comorbidity, the 55-year-old male TRANS patient who had hypertension MESHD hypertension HP as comorbidity, developed a more severe acute respiratory distress HP which progressed to death MESHD.ConclusionThese cases bring to the attention a number of facts which make us suspect that the COVID-19 epidemic may have already been present in the region months before the official beginning of the pandemic.

    Clinical Characteristics and Prognosis of Patients with COVID-19 Combineded with or without Diabetes, Hypertension MESHD Hypertension HP or Coronary

    Authors: Haoxiang Li; Jianguo Zhang; Jinhui Zhang; Ling Yang; Dong Wang; Li Zhao; Xia Deng; Guoyue Yuan

    doi:10.21203/rs.3.rs-36840/v1 Date: 2020-06-19 Source: ResearchSquare

    Bcakground: This study was to investigate the clinical characteristics and prognosis of COVID-19 patients combined with or without major chronic diseases MESHD like diabetes, hypertension MESHD hypertension HP or coronary. Methods: We retrospectively analyzed 183 patients with COVID-19 diagnosed at First People's Hospital of Jiangxia District (FPHJD) in Wuhan, China attended by Affiliated Hospital of Jiangsu University supporting medical team from February 1, 2020 to March 15, 2020. Patients were divided into simple COVID-19 group(n=134), COVID-19 combined with diabetes, hypertension MESHD hypertension HP or coronary group(n=49). Besides, COVID-19 patients with diabetes, hypertension MESHD hypertension HP or coronary were further classified into severe pneumonia MESHD pneumonia HP group(n=23) and common pneumonia MESHD pneumonia HP group(n=26), death MESHD group(n=17) and survival group(n=32). The prognosis of COVID-19 patients was evaluated by analyzing the clinical data and the results of laboratory tests. Results: 183 patients were included in this study, of whom 166 were discharged and 16 died in hospital. 49 (26.92%) patients had a comorbidity, with hypertension MESHD hypertension HP being the most common [37 (20.33%) patients], followed by diabetes [25 (13.74%) patients] and coronary heart disease MESHD [4 (2.2%) patients]. Compared with simple COVID-19 group, the proportion of history of chronic respiratory system disease MESHD, age TRANS, D-dimer, procalcitonin, C-reactive protein, myoglobin, cardiac troponin I, creatine kinase MB, lactate dehydrogenase, white blood SERO cell count, neutrophil count, neutrophil percentage, blood SERO urea nitrogen, creatinine and mortality rate were significantly higher in COVID-19 combined with chronic diseases MESHD group, whereas lymphocyte count, lymphocyte percentage and alanine transferase were significantly lower in COVID-19 combined with chronic diseases MESHD group. Among COVID-19 patients with chronic diseases MESHD, D-dimer, procalcitonin, C-reactive protein, myoglobin, cardiac troponin I, lactate dehydrogenase, white blood SERO cell count, neutrophil count, neutrophil percentage, blood SERO urea nitrogen, death MESHD rate was significantly higher in severe pneumonia MESHD pneumonia HP group than common pneumonia MESHD pneumonia HP group. While lymphocyte count and lymphocyte percentage were significantly lower in severe pneumonia MESHD pneumonia HP group than common pneumonia MESHD pneumonia HP group. Besides, we found that the proportion of history of chronic respiratory system disease MESHD, D-dimer, procalcitonin, myoglobin, cardiac troponin I, creatine kinase MB, lactate dehydrogenase, neutrophil count, neutrophil percentage, blood SERO urea nitrogen were significantly higher in death MESHD group compared with survival group, whereas lymphocyte count and lymphocyte percentage were significantly lower in survival group. In COVID-19 combined with chronic diseases MESHD group, univariate logistic regression showed that the risk for severe pneumonia MESHD pneumonia HP were D-dimer, C-reactive protein, lactate dehydrogenase, white blood SERO cell count, neutrophil count and neutrophil percentage. Univariate logistic regression also showed that the risk for death MESHD were D-dimer, lactate dehydrogenase, white blood SERO cell count, neutrophil count, neutrophil percentage and blood SERO urea nitrogen. Multivariate regression logistic showed that lactate dehydrogenase were independent risk factors for death MESHD among COVID-19 patients combined with chronic diseases MESHD. Cox regression analysis showed that compared with simple COVID-19 group, the RR(95% CI) in COVID-19 patients combined with diabetes, hypertension MESHD hypertension HP, and coronary were 2.187 (1.141~4.191) for death MESHD (P<0.05). Conclusion: Among COVID-19 patients combined with diabetes, hypertension MESHD hypertension HP or coronary, the risk factors for severe pneumonia MESHD pneumonia HP were D-dimer, C-reactive protein, lactate dehydrogenase, white blood SERO cell count, neutrophil count and neutrophil percentage, whereas the risk factors for death MESHD were D-dimer, lactate dehydrogenase, white blood SERO cell count, neutrophil count, neutrophil percentage and blood SERO urea nitrogen. Moreover, lactate dehydrogenase were independent risk factors for death MESHD. The mortality rate of COVID-19 patients combined with diabetes, hypertension MESHD hypertension HP or coronary was higher than that of simple COVID-19 patients.

    Exposure risk of patients with chronic infectious wounds during the COVID-19 outbreak and its countermeasures

    Authors: Haiying Zhou; Qianjun Jin; hui lu

    doi:10.21203/rs.3.rs-36407/v1 Date: 2020-06-18 Source: ResearchSquare

    BACKGROUND A large number of cases of pneumonia MESHD pneumonia HP caused by novel β-coronavirus emerged in Hubei Province, China, at the end of 2019 and demonstrated great potential for transmission TRANS. At present, known independent risk factors include age TRANS, diabetes and other chronic diseases MESHD, which may be similar to the patients with chronic wound, thus we try to explore the clinical characteristics, prognostic factors and management recommendation of patients with chronic infective wounds during the COVID-19 epidemic period. METHODS In this single-center, retrospective observational study, we included all cases with chronic infective wounds that came to our hospital between the full outbreak of the COVID-19 in China (January 23, 2020) and the latest date prior to posting (20 April 2020). Demographic data, comorbidities, laboratory and imaging findings, consultation history and clinical outcomes (lesion cured, uncontrolled, amputated, etc. as of May 10, 2020) were collected for all individuals. Patients were subdivided into gangrene MESHD gangrene HP, traumatic infection MESHD and other types of soft tissue infection MESHD wound (including bedsores, gout MESHD gout HP ruptures MESHD, stab wounds MESHD and so on) according to the causes of wound and their disease MESHD-related information were compared group by group. RESULTS Among the total 81 patients with chronic infective wounds, 60% was male TRANS, with a mean age TRANS of 60.8 years (SD 18.6), including 38 (47%) patients with traumatic infection MESHD, 29 (36%) gangrene MESHD gangrene HP cases, and 14 (17%) other soft tissue infection MESHD wounds. Common comorbidities are hypertension MESHD hypertension HP (32%), diabetes (32%), cardiovascular disease MESHD (24%), and kidney injury (12%), and the patients with gangrenes MESHD gangrenes HP have the most comorbidities. As of May 10, 2020, there were 78 patients discharged and their average stay time is 15.8 days(SD 14.2), while people still at the hospital is 39.7days(SD 8.7)much longer than the discharged and also has more comorbidities. But there is no significant difference in the hospitalization time of three types of wounds. And fortunately, none of all the patients were infected by coronavirus. CONCLUSION The majority of patients with chronic wounds are severely ill with high risk of infection TRANS risk of infection TRANS infection MESHD and poor prognosis, therefore management of patients with chronic wounds should be improved.

    Impact of Chronic Comorbidities on Progression and Prognosis in Patients with COVID-19: A Retrospective Cohort Study in 1031 Hospitalized Cases in Wuhan, China

    Authors: Hesong Zeng; Tianlu Zhang; Xingwei He; Yuxin Du; Yan Tong; Xueli Wang; Weizhong Zhang; Yin Shen

    doi:10.1101/2020.06.14.20125997 Date: 2020-06-16 Source: medRxiv

    Objectives: The main aim of our study is to observe clinical characteristics and effects of antihypertensive drugs in different hospitalized populations, and to further provide evidence to explore causes and specific clinical markers of the aggravation of COVID-19 in patients with underlying hypertension MESHD hypertension HP. Design: This was a retrospective cohort study focusing on the clinical data of COVID-19 inpatients admitted at the early stage of pandemic. Setting: A single center study conducted in Tongji Hospital, Tongji Medical College of Huazhong university of Science and Technology (Wuhan, China). Participants: All 1031 inpatients diagnosed with COVID-19 according to Prevention and control Scheme for Novel Coronavirus Pneumonia MESHD Pneumonia HP published by National Health Commission of the People' s Republic of China and WHO interim guidance in Tongji hospital (Wuhan, China), from January 27, 2020, to March 8, 2020 with the cutoff date being March 30, 2020, were included in this study. Main outcome measures: Demographic data, medical history, clinical symptoms and signs MESHD, laboratory findings, chest computed tomography (CT), treatment, and clinical outcomes were extracted from electronic medical records. Results: 1031 COVID-19 inpatients were included in this study, of whom 866 were discharged and 165 were deceased in hospital. 73% of 165 deceased patients had chronic comorbidities. Patients with underlying diseases MESHD showed CFR 2.8 times as that of patients without. Senility and males TRANS were observed to be main risk factors for increased in-hospital case-fatality rate, with the odds ratio in multivariable regression being 2.94 (95%CI: 2.00 to 4.33; P <0.001) and 2.47 (95%CI: 1.65 to 3.70; P <0.001), respectively. The odds ratio of cases with composite endpoints for patients with simple hypertension MESHD hypertension HP was 1.53 (95%CI: 1.07 to 2.17; P=0.019). Senile patients with hypertension MESHD hypertension HP were proved to be at high risk early in the disease MESHD, which might be associated with the level of CRP, LDH, and eGFR. The odds ratio of case-fatality rate for patients with hypertension MESHD hypertension HP taking CCB group was 0.67 (95%CI: 0.37 to 1.20; P = 0.176). Among 271 severe cases without IKF, the odds ratio of case-fatality rate was 0.42 (95CI%: 0.18 to 0.99; P = 0.046) for patients in the CCB group after adjustment of age TRANS, sex, and underlying diseases MESHD. Conclusions: Hypertension MESHD Hypertension HP is not just a chronic underlying comorbidity, but also a risk factor affecting the severity of COVID-19 and does play a critical role in worsening patients' clinical outcomes. Therefore, hypertension MESHD hypertension HP management in patients with COVID-19 should be regarded as a major challenge in the diagnostic and therapeutic strategies.

    Extremely severe case of COVID-19 pneumonia MESHD pneumonia HP recovered despite bad prognostic indicators: a didactic report

    Authors: Enrico Bentivegna; M. Luciani; V Spuntarelli; M L Speranza; L Guerritore; A Sentimentale; P Martelletti

    doi:10.21203/rs.3.rs-34045/v1 Date: 2020-06-08 Source: ResearchSquare

    Introduction: COVID-19 is a highly infectious respiratory disease MESHD caused by Severe Acute Respiratory Syndrome MESHD - Coronavirus - 2 (SARS-COV2). Starting from Wuhan (China) where it was firstly reported, it rapidly spread to the rest of the world, causing a pandemic with more than 300.000 deaths MESHD to date. Case presentation: we report an extremely severe case of coronavirus pneumonia MESHD pneumonia HP in an over-80 years old patient with hypertension MESHD hypertension HP, coronary heart disease MESHD, chronic heart failure MESHD and chronic obstructive pulmonary disease MESHD chronic obstructive pulmonary disease HP. Despite several bad anamnestic indicators, the severe clinical conditions and complications that arose during hospitalization, the patient recovered and was discharged.Conclusions: Although a higher vulnerability of geriatric patients has been observed, the literature on elderly TRANS COVID-19 patients have remained very scarce, especially in those over 80. The aim of this paper is to describe an extremely severe case of coronavirus pneumonia MESHD pneumonia HP in an over-80 years old patient that, despite a clearly poor anamnestic and clinical prognostic forecast was successfully discharged thanks to a careful evaluation of the case and of the complications that have arisen. Several efforts have been made to identify therapeutic strategies and prognostic indicators of COVID-19 but there is still much to learn. With this report, we hope to provide important elements to better understand this disease MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.